Replimune Group, Inc. (REPL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Replimune Group, Inc. (REPL) trades at $11.54 with AI Score 22/100 (Grade F). Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immuno-gene therapies for cancer. Market cap: $968.73M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026REPL stock analysis for 2026: Analysts have set a consensus price target of $14.00 for Replimune Group, Inc., suggesting 21.3% upside from the current price of $11.54. The AI MoonshotScore is 22/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
REPL: 1/1 perspectives are bearish.
How is this calculated? →Replimune Group, Inc. (REPL) Healthcare & Pipeline Overview
Replimune Group, Inc. pioneers oncolytic immuno-gene therapies, leveraging its proprietary Immunotherapy platform to combat cancer. With lead candidate RP1 in Phase I/II and Phase II trials, and RP2 and RP3 in Phase I, the company targets solid tumors and cutaneous squamous cell carcinoma, positioning itself in the competitive biotechnology landscape.
What Is the Investment Thesis for REPL?
Replimune Group, Inc. presents a compelling investment thesis centered on its innovative oncolytic immuno-gene therapy platform. The company's lead candidate, RP1, is currently in Phase I/II and Phase II clinical trials, targeting a range of solid tumors and cutaneous squamous cell carcinoma, respectively. Success in these trials could drive significant value. Further potential lies in the development of RP2 and RP3, both in Phase I clinical trials, expanding the company's pipeline and addressing different mechanisms of immune activation. However, the biotechnology sector is inherently risky, with clinical trial outcomes and regulatory approvals posing significant uncertainties. With a market capitalization of $968.73M, Replimune's valuation reflects both the potential upside and the inherent risks associated with its developmental stage and the broader biotechnology industry.
Based on FMP financials and quantitative analysis
REPL Key Highlights
- RP1, Replimune's lead product candidate, is in Phase I/II clinical trials for a range of solid tumors, indicating progress in its development pipeline.
- RP1 is also in Phase II clinical trials for patients with cutaneous squamous cell carcinoma, potentially addressing a specific market need.
- The company is developing RP2 and RP3, both in Phase I clinical trials, expanding its portfolio of oncolytic immuno-gene therapies.
- Replimune's proprietary Immunotherapy platform is a key asset, enabling the design and development of novel cancer treatments.
- The company employs 479 individuals, reflecting its investment in research and development activities.
Who Are REPL's Competitors?
REPL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REPL's Key Strengths?
- Proprietary Immunotherapy platform.
- Promising clinical trial results for RP1.
- Pipeline of multiple oncolytic immuno-gene therapy candidates.
- Experienced management team.
What Are REPL's Weaknesses?
- Limited commercialized products and revenue.
- Reliance on clinical trial success and regulatory approvals.
- High research and development costs.
- Competition from larger pharmaceutical companies.
What Could Drive REPL Stock Higher?
- Data readout from Phase I/II clinical trials of RP1 for solid tumors.
- Data readout from Phase II clinical trial of RP1 for cutaneous squamous cell carcinoma.
- Advancement of RP2 and RP3 into later-stage clinical trials.
- Expansion of clinical trial sites and patient enrollment.
- Potential for strategic partnerships and collaborations.
What Are the Key Risks for REPL?
- Financial-distress signal — its Altman Z-Score of -4.13 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory setbacks or rejection of product candidates.
- Competition from other cancer therapies.
- High research and development costs.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for REPL?
- Expansion of RP1 Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for RP1 to include additional solid tumor types and stages. Positive results from these trials could lead to accelerated regulatory approval and broader market access. The global market for solid tumor therapies is estimated to reach $400 billion by 2028, providing a substantial addressable market for RP1 if it proves effective and safe.
- Advancement of RP2 and RP3 Programs: The successful advancement of RP2 and RP3 through clinical trials represents another key growth opportunity. These product candidates target different mechanisms of immune activation, potentially broadening Replimune's therapeutic reach and addressing unmet needs in cancer treatment. The market for immunotherapies is projected to continue growing rapidly, driven by their effectiveness in treating various cancers.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Replimune with access to additional resources, expertise, and funding. Collaborations can accelerate the development and commercialization of its product candidates, as well as expand its research capabilities. Such partnerships are common in the biotechnology industry and can significantly enhance a company's growth prospects.
- Geographic Expansion: Expanding its operations and clinical trials to new geographic regions, particularly in Asia and Europe, represents a growth opportunity for Replimune. These regions have large patient populations and growing healthcare markets. Establishing a presence in these markets could increase the company's revenue potential and diversify its geographic risk.
- Acquisition or Licensing of New Technologies: Acquiring or licensing new technologies that complement its existing platform could enhance Replimune's competitive position and expand its product pipeline. This could include technologies related to gene therapy, immunotherapy, or drug delivery. Such acquisitions can provide access to new intellectual property and expertise, accelerating the development of innovative cancer therapies.
What Opportunities Does REPL Have?
- Expansion of clinical trials to new indications.
- Strategic partnerships and collaborations.
- Geographic expansion into new markets.
- Acquisition or licensing of new technologies.
What Threats Does REPL Face?
- Clinical trial failures.
- Regulatory setbacks.
- Competition from other cancer therapies.
- Patent expirations.
What Are REPL's Competitive Advantages?
- Proprietary Immunotherapy platform for developing oncolytic viruses.
- Patent protection for its product candidates and technologies.
- Clinical trial data demonstrating the efficacy and safety of its therapies.
- Expertise in oncolytic virus development and immuno-oncology.
What Does REPL Do?
Replimune Group, Inc., founded in 2015 and headquartered in Woburn, Massachusetts, is a biotechnology company dedicated to developing oncolytic immuno-gene therapies for the treatment of cancer. The company operates on its proprietary Immunotherapy platform, which is used to design and develop product candidates aimed at activating the immune system against cancer cells. Replimune's lead product candidate, RP1, is a selectively replicating version of the herpes simplex virus 1 (HSV-1). RP1 is currently undergoing Phase I/II clinical trials for a range of solid tumors and a Phase II clinical trial for patients with cutaneous squamous cell carcinoma (CSCC). In addition to RP1, Replimune is developing RP2, which is in Phase I clinical trials and is designed to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response caused by CTLA-4. The company is also developing RP3, which is in Phase I clinical trials and is engineered to express immune-activating proteins that stimulate T cells. Replimune's focus on innovative immuno-gene therapies positions it within the competitive landscape of the biotechnology industry, where it aims to address unmet needs in cancer treatment.
What Products and Services Does REPL Offer?
- Develop oncolytic immuno-gene therapies for cancer treatment.
- Utilize a proprietary Immunotherapy platform to design product candidates.
- Focus on activating the immune system against cancer cells.
- Conduct clinical trials for various product candidates.
- Develop RP1, a selectively replicating version of herpes simplex virus 1.
- Develop RP2, designed to block the inhibition of the immune response caused by CTLA-4.
- Develop RP3, engineered to express immune-activating proteins that stimulate T cells.
How Does REPL Make Money?
- Develop and commercialize oncolytic immuno-gene therapies.
- Generate revenue through the sale of approved therapies.
- Potentially generate revenue through licensing agreements and partnerships.
- Fund research and development through venture capital and public offerings.
What Industry Does REPL Operate In?
Replimune Group, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Replimune are at the forefront of developing innovative treatments, including oncolytic viruses and immuno-gene therapies. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms, all vying for market share in this rapidly evolving field. Success hinges on clinical trial outcomes, regulatory approvals, and the ability to effectively commercialize novel therapies.
Who Are REPL's Key Customers?
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Patients with various types of cancer.
- Potential pharmaceutical partners for licensing and collaboration.
F-Score 2/9Financial Health
Replimune Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.13 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -94.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.7%, the inverse of the P/E and a quick read on earnings relative to price.
Replimune Group, Inc. (REPL) Valuation Context
Valued at $968.73M, REPL is classified as a small-cap stock. Relative to its peer group, REPL's quantitative score of 22/100 is below the peer average of 82/100.
FY2026 estForward Outlook
Wall Street analysts project Replimune Group, Inc. revenue of about $4.4M for fiscal 2026, with EPS near $-3.25. The estimate reflects 5 contributing analysts.
REPL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Replimune's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has turned increasingly positive as investors recognize the potential of its innovative therapies in the oncology space.
- Recent clinical trial results have garnered attention, highlighting the effectiveness of their treatments, which may attract more investors.
- The growing interest in immunotherapy in the market aligns well with Replimune's focus, suggesting a favorable environment for its growth.
Bear Case
- Concerns about the competitive landscape in the immunotherapy sector could dampen investor enthusiasm, as larger players may overshadow smaller firms like Replimune.
- Recent fluctuations in community sentiment reflect uncertainty about the company's ability to deliver on its promises, leading to mixed opinions among investors.
- Ongoing regulatory hurdles in the biotech industry may pose risks to Replimune's timelines and market entry, causing caution among traders.
- Market perception remains cautious due to the volatility often associated with biotech stocks, which could deter risk-averse investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
REPL Latest News
-
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga · Jun 30, 2026
-
What's Going On With Capricor Therapeutics Stock On Friday?
benzinga · Jun 26, 2026
-
Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today
benzinga · Jun 1, 2026
-
Stocks to Watch Recap: Dell, Gap, Costco, SentinelOne
The Wall Street Journal · May 29, 2026
REPL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REPL.
Price Targets
Consensus target: $14.00
REPL MoonshotScore
What does this score mean?
The MoonshotScore rates REPL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
What's Going On With Capricor Therapeutics Stock On Friday?
Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today
Stocks to Watch Recap: Dell, Gap, Costco, SentinelOne
Latest Replimune Group, Inc. Analysis
Palo Alto Networks Surges 9.28% as Dow Climbs 0.72%
5 min readHealthcare Sector Gains as Replimune Soars 85.68% on Promising Cancer Data
3 min readREPL Stock Rockets 85.68% After Promising Cancer Therapy Data at ASCO
3 min readMicrosoft Jumps 5.45% as Healthcare Sector Sees Mixed Signals from ASCO
3 min readPHR Gains 4.90% as Focus Shifts to Healthcare; DIA Dips -0.55%
4 min readLeadership: Sushil Patel
CEO
Sushil Patel is the Chief Executive Officer of Replimune Group, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in various companies, focusing on corporate strategy, business development, and commercial operations. Patel's expertise spans across multiple therapeutic areas, including oncology and immunology. He is responsible for guiding Replimune's strategic direction and overseeing its research and development efforts.
Track Record: Under Sushil Patel's leadership, Replimune has advanced its lead product candidate, RP1, through clinical trials and expanded its pipeline with RP2 and RP3. He has also overseen the company's fundraising efforts and strategic partnerships. Patel's focus has been on building a strong team and fostering a culture of innovation within the company.
What Investors Ask About Replimune Group, Inc. (REPL) — Healthcare
What does Replimune Group, Inc. do?
Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immuno-gene therapies for the treatment of cancer. The company utilizes its proprietary Immunotherapy platform to design and develop product candidates that activate the immune system against cancer cells. Its lead product candidate, RP1, is a selectively replicating version of the herpes simplex virus 1 (HSV-1) and is currently in Phase I/II clinical trials for a range of solid tumors and Phase II clinical trials for patients with cutaneous squamous cell carcinoma. Replimune also has RP2 and RP3 in Phase I clinical trials.
What do analysts say about REPL stock?
Analyst coverage of Replimune Group, Inc. typically focuses on the potential of its oncolytic immuno-gene therapy platform and the progress of its clinical trials. Key valuation metrics include market capitalization, cash runway, and potential revenue from future product sales. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization of its product candidates. Analyst ratings and price targets reflect these factors, but it's important to note that the biotechnology sector is inherently risky and subject to significant volatility.
What are the main risks for REPL?
The main risks for Replimune Group, Inc. include the inherent uncertainties of clinical trial outcomes, potential regulatory setbacks, and competition from other cancer therapies. Clinical trial failures or delays could significantly impact the company's valuation and future prospects. Regulatory agencies may not approve its product candidates, or may require additional clinical trials. Competition from larger pharmaceutical companies with more resources and established market positions also poses a threat. Additionally, Replimune faces risks related to intellectual property protection, manufacturing, and commercialization.
How does Replimune Group, Inc. manage patent expiration risks?
As a biotechnology company, Replimune Group, Inc. faces patent expiration risks that could impact the exclusivity and revenue potential of its therapies. To mitigate these risks, Replimune likely employs several strategies, including filing patent applications for new inventions, formulations, and methods of use related to its oncolytic immuno-gene therapies. The company also seeks to extend patent protection through strategies such as developing new formulations or combinations of its therapies. Furthermore, Replimune may pursue strategic collaborations or acquisitions to gain access to new intellectual property and technologies.
What revenue streams does Replimune Group, Inc. have in healthcare?
Currently, Replimune Group, Inc., as a clinical-stage biotechnology company, does not have significant revenue streams from commercialized products. Its primary focus is on research and development, and its revenue is primarily derived from collaborations, licensing agreements, and potential milestone payments. As its product candidates, such as RP1, RP2, and RP3, advance through clinical trials and potentially gain regulatory approval, Replimune anticipates generating revenue through the sale of its therapies to hospitals, cancer treatment centers, and other healthcare providers. The specific revenue streams will depend on the pricing, market access, and adoption of its therapies.
What are the key factors to evaluate for REPL?
Replimune Group, Inc. (REPL) holds an AI score of 22/100 (low). Analysts target $14.00 (+21%). Not financial advice.
How frequently does REPL data refresh on this page?
REPL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven REPL's recent stock price performance?
Replimune Group, Inc. (REPL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Immunotherapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.